Both a characteristic clinical syndrome and positive amyloid beta and tau markers are needed for reliable diagnosis, advise new recommendations from an international expert group.
Emerging Blood-Based Biomarkers for Alzheimer Disease: A Status Report
A screening blood test could accelerate drug development and enable earlier, more effective intervention. We offer an overview of promising efforts in pursuit of a reliable blood-based biomarker.